RMD

ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2007

Business Context and Reporting Period

Company: ResMed Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended June 30, 2007
Business Overview: ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates as a single segment, selling airflow generators, mask systems, and diagnostic products in over 68 countries. Principal manufacturing is located in Sydney, Australia, with additional facilities in France and the U.S.

Key Financial Metrics

Note: Gross margin decline is primarily due to a $59.7 million voluntary product recall expense included in cost of sales.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 18% to $716.3 million, driven by a 15% organic growth in unit sales and a $20.5 million favorable impact from foreign currency movements.
• Product Recall Impact: A significant one-time charge of $59.7 million was recognized for a voluntary recall of approximately 300,000 S8 flow generators due to a potential short circuit in the power connector. This reduced operating income by approximately $41.8 million on an after-tax basis.
• Profitability: Net income decreased 25% to $66.3 million. Excluding the recall expense, diluted EPS would have been $1.38, representing a 19% increase over the prior year.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 19% to $237.3 million, and R&D expenses increased 35% to $50.1 million, reflecting headcount growth, infrastructure investment, and currency effects.
• Balance Sheet: Inventories increased 35% to $157.2 million to support new product launches and sales growth. Accounts receivable increased 21% to $167.8 million, with days sales outstanding rising from 70 to 77 days.

Guidance, Outlook, and Risks

• Outlook: Management expects SG&A expenses to remain in the historical range of 32% to 34% of revenue and R&D expenses to remain between 6% and 7% of revenue.
• Product Pipeline: Continued focus on innovation with recent launches of the Mirage Quattro, Mirage Liberty, and VPAP Malibu. Expansion into new clinical applications for central sleep apnea and heart failure (Adapt SV) is ongoing.
• Key Risks:
  • Product Recall: Uncertainty regarding the final cost of the S8 recall and potential reputational damage affecting physician and customer confidence.
  • Reimbursement: Dependence on third-party payers (Medicare, Medicaid, private insurers) and potential legislative changes reducing reimbursement rates or implementing competitive bidding.
  • Foreign Currency: Significant exposure to fluctuations in the Australian dollar and Euro, which impact both revenue translation and manufacturing costs.
  • Regulatory: Compliance with FDA and international regulations; potential delays in new product clearances.

Investor Verification Checklist

• Recall Cost Accuracy: Verify if the actual costs of the S8 recall exceed the $59.7 million accrual and monitor for any additional product liability claims.
• Reimbursement Trends: Monitor legislative developments regarding Medicare competitive bidding for Durable Medical Equipment (DME) and its impact on North American margins.
• Currency Hedging: Assess the effectiveness of the company's foreign currency hedging program given the significant portion of revenue and costs denominated in non-USD currencies.
• Inventory Levels: Track inventory turnover to ensure the 35% increase in inventory does not lead to obsolescence or write-downs as new products are introduced.
• Debt Covenants: Confirm continued compliance with financial covenants on the Syndicated Facility Agreement and Revolving Loan Agreement, particularly the debt-to-EBITDA ratio.